• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ARIPIPRAZOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • ARIPIPRAZOLE chembl:CHEMBL1112 Approved

    Alternate Names:

    OPC-31
    OPC-14597
    ARIPIPRAZOLE
    ABILIFY MAINTENA
    ABILIFY MYCITE KIT
    ABILIFY MAINTENA KIT
    ABILIFY
    ARIPIPREX
    OPC 14597
    ABILITAT
    OPC 31
    ARIPIPRAZOL
    ARIPIPRAZOLUM
    pubchem.compound:60795
    chembl:CHEMBL1112
    rxcui:89013
    drugbank:01238
    chemidplus:129722-12-9

    Drug Info:

    Drug Class antipsychotic agents
    Year of Approval 2002
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antipsychotic agent
    (3 More Sources)

    Publications:

    Inoue et al., 1997, Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum., Eur. J. Pharmacol.
    Wood et al., 2007, Aripiprazole acts as a selective dopamine D2 receptor partial agonist., Expert Opin Investig Drugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Hirose et al., 2005, Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist., J. Med. Invest.
    Wood et al., 2006, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties., Eur. J. Pharmacol.
    Kim et al., 2006, Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study., Hum Psychopharmacol
    Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
    Lawler CP et al., 1999, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes., Neuropsychopharmacology
    Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
    Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Huertas E et al., 2010, The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming., Genes Brain Behav
    Hirvonen MM et al., 2009, C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity., Synapse
    Betcheva ET et al., 2009, Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population., J Hum Genet
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Crettol S et al., 2008, Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment., Prog Neuropsychopharmacol Biol Psychiatry
    Allen NC et al., 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database., Nat Genet
    Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
    Hoenicka J et al., 2006, C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients., Acta Psychiatr Scand
    Hänninen K et al., 2006, Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia., Neurosci Lett
    Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Lawford BR et al., 2005, The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia., Schizophr Res
    Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
    Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
    de Bartolomeis A et al., 2015, Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism., CNS Drugs
    Marona-Lewicka et al., 2004, Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats., Psychopharmacology (Berl.)
    Cosi et al., 2005, Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation., Brain Res.
    Jordan et al., 2002, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor., Eur. J. Pharmacol.
    Jordan et al., 2004, In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function., Eur. J. Pharmacol.
    Swainston Harrison et al., 2004, Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder., Drugs
    Stark et al., 2007, Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies., Psychopharmacology (Berl.)
    Bortolozzi et al., 2007, In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain., Psychopharmacology (Berl.)
    Meltzer et al., 2003, Serotonin receptors: their key role in drugs to treat schizophrenia., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Serretti A et al., 2009, Influence of TAAR6 polymorphisms on response to aripiprazole., Prog Neuropsychopharmacol Biol Psychiatry
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
    Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
    Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
  • ARIPIPRAZOLE   TAAR6

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19345712


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   MC4R

    Interaction Score: 1.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27217270 23920449 23799528 22566560


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   ANKK1

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18926547 18855532


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   RABEP1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   SH2B1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Abilify
    Novel drug target Established target
    Mechanism of Interaction Dopamine D2 receptor partial agonist

    PMIDs:
    9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ARIPIPRAZOLE   HTR1A

    Interaction Score: 0.83

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 1a (5-HT1a) receptor partial agonist
    Trial Name Abilify

    PMIDs:
    14647959 15862515 12063084 14709325 15257633 26346901


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • ARIPIPRAZOLE   CNR1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23799528 20631561 20107430


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   FAAH

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20631561


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   HTR2A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist
    Trial Name Abilify

    PMIDs:
    17242925 17265076 14642974 26346901


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • ARIPIPRAZOLE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29443543


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TEND: ARIPIPRAZOLE

    • Version: 01-August-2011

    Alternate Names:
    ARIPIPRAZOLE Primary Drug Name

    Drug Info:
    Year of Approval 2002
    Drug Class antipsychotic agents

    Publications:

  • TdgClinicalTrial: ARIPIPRAZOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antipsychotic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: aripiprazole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry

  • TTD: Aripiprazole

    • Version: 2020.06.01

    Alternate Names:
    D0H3HM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1112

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1112

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Aripiprazole

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21